Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.55 |
| ▸ | FPR2 | P25090 | 4/20 | 0.53 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5954543 | 1.00 | SCN9A (0.55) | SCN9AFPR2FNTAFNTBEPHX2 | |
| SCHEMBL233006 | 0.90 | CA12 (0.48) | SCN9AFPR2MMP2ALDH1A1 | |
| SCHEMBL233005 | 0.90 | CA12 (0.48) | SCN9AFPR2MMP2ALDH1A1 | |
| Methane SCHEMBL28130556 | 0.88 | CA12 (0.47) | SCN9AFPR2MMP2ALDH1A1 | |
| SCHEMBL5955152 | 0.87 | MMP2 (0.57) | MAPK1MMP2MMP8MMP14CA9 | |
| SCHEMBL5955145 | 0.87 | MMP2 (0.57) | MAPK1MMP2MMP8MMP14CA9 | |
| SCHEMBL5954848 | 0.85 | MEN1 (0.47) | MAPK1MMP2MMP8MMP14CA9 | |
| SCHEMBL5954851 | 0.85 | MEN1 (0.47) | MAPK1MMP2MMP8MMP14CA9 | |
| SCHEMBL6169593 | 0.84 | CA2 (0.56) | FNTAFNTBMMP2MMP8MMP14 | |
| SCHEMBL6169592 | 0.84 | CA2 (0.56) | FNTAFNTBMMP2MMP8MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LABORATOIRES FOURNIER S.A. (FR) | 2006-02-02 | — | — | US | disclosed |
| EP-1546111-A2 | 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES | LABORATOIRES FOURNIER S.A. (FR) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004031160-A2 | 2-THIOHYDANTOINE DERIVATIVE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF DIABETES | LABORATOIRES FOURNIER S.A. (FR) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025589-A1 | 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes | LIPC, CYP4F2, SLC5A2 | SCN9A 2953/4885FPR2 2049/4885FNTA 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.